Phaseline

Companies › Arcus Biosciences

Arcus Biosciences: clinical trials, targets and expected readouts

7 active drug programs in 20 registered trials: 9 Phase 2, 9 Phase 1, 2 Phase 3; Oncology, Gastroenterology, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
casdatifan
Adenosine A2A receptor antagonist
ADORA2APhase 3Metastatic Clear Cell Renal Cell Carcinoma; Healthy Participants; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma …May 2027
Quemliclustat
CD73 inhibitor
NT5EPhase 3Metastatic Pancreatic Ductal Adenocarcinoma; Gastrointestinal Tract Malignancies; Oligometastatic Prostate Cancer; Biliary Tract Carcinoma …Nov 2030
zimberelimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 2Gastrointestinal Tract Malignancies; Non Small Cell Lung Cancer; Advanced Cancer; Clear Cell Renal Cell CarcinomaSep 2027
Domvanalimab
T-cell immunoreceptor with Ig and ITIM domains inhibitor
TIGITPhase 2Gastrointestinal Tract Malignancies; Non Small Cell Lung Cancer–
AB102–Phase 1Healthy VolunteersDec 2026
AB598–Phase 1Advanced CancerSep 2027
AB801
Adenosine A2A receptor antagonist
–Phase 1Advanced Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06120075AB801Phase 1Advanced CancerOncologyApr 2026
NCT05329766QuemliclustatPhase 2Gastrointestinal Tract MalignanciesOncologySep 2026
NCT05329766zimberelimabPhase 2Gastrointestinal Tract MalignanciesOncologySep 2026
NCT05329766DomvanalimabPhase 2Gastrointestinal Tract MalignanciesOncologySep 2026
NCT04736173zimberelimabPhase 2Non Small Cell Lung CancerOncologySep 2026
NCT04736173DomvanalimabPhase 2Non Small Cell Lung CancerOncologySep 2026
NCT05915442QuemliclustatPhase 2Oligometastatic Prostate CancerOncologyDec 2026
NCT06048133QuemliclustatPhase 2Biliary Tract CarcinomaOncologyDec 2026
NCT07662057AB102Phase 1Healthy VolunteersOtherDec 2026
NCT06048484QuemliclustatPhase 2Pancreatic Ductal AdenocarcinomaOncologyApr 2027
NCT07751250casdatifanPhase 1Healthy ParticipantsGastroenterologyMay 2027
NCT05891171zimberelimabPhase 1Advanced CancerOncologySep 2027
NCT05891171AB598Phase 1Advanced CancerOncologySep 2027
NCT07397611casdatifanPhase 2Renal Cell CarcinomaOncologyJan 2028
NCT07011719casdatifanPhase 3Metastatic Clear Cell Renal Cell CarcinomaOncologyApr 2028
NCT05536141casdatifanPhase 1Clear Cell Renal Cell CarcinomaOncologyMar 2029
NCT05536141zimberelimabPhase 1Clear Cell Renal Cell CarcinomaOncologyMar 2029
NCT07667335QuemliclustatPhase 1Locally Advanced Bladder Urothelial CarcinomaOncologyJul 2029
NCT07748988casdatifanPhase 1Refractory Clear Cell Renal Cell CarcinomaOncologyJul 2030
NCT06608927QuemliclustatPhase 3Metastatic Pancreatic Ductal AdenocarcinomaOncologyNov 2030

From the company's SEC filings

Cash and short-term investments of $630m on 2026-09-30; operating cash outflow about $463m a year; runway about 16 months at that burn, to Feb 2028; 4 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

NT5E (1) ADORA2A (1) PDCD1 (1) TIGIT (1)

Companies with the same targets

AstraZeneca Akeso Shanghai Henlius Biotech Gilead Sciences Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience

Companies built like this

Kura Oncology Eikon Therapeutics ALX Oncology CSPC Megalith Biopharmaceutical Chipscreen Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.